Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04655885
Other study ID # OPTILIVER TRIAL-IPC 2018-022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 3, 2022
Est. completion date May 15, 2026

Study information

Verified date April 2024
Source Institut Paoli-Calmettes
Contact Dominique GENRE, MD
Phone +33 4 91 22 37 78
Email drci.up@ipc.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Major hepatectomies are high-risk surgeries offered more and more frequently for the curative treatment of primary or secondary liver cancer, and for complex cases, representing a real challenge for medical teams. The 1st peroperative phase of "hepatic resection" requires a minimum supply of filling fluids to limit perioperative bleeding (Low Central Venous Pressure). However this strategy exposes the risk of organ hypoperfusion due to low cardiac flow, secondary to hypovolaemia, which may lead to ischemic situations favoring the onset of postoperative complications. On the other hand, the hemodynamic management of the 2nd peroperative phase "post hepatic resection" is marked by the need to correct this hypoperfusion by optimizing cardiac output by suitable vascular filling. The major challenge is thus to restore cardiac output by refilling without excess, by correcting the hypovolemia that arose during the "post resection of the hepatic parenchyma" phase. Our hypothesis is that an individualized protocol for optimizing intraoperative cardiac flow by guided vascular filling during the "post hepatic resection" phase is accompanied by a reduction in postoperative complications in patients operated on for major hepatic surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 186
Est. completion date May 15, 2026
Est. primary completion date March 15, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years old, 2. Signature of consent, 3. Any patient scheduled for major hepatic surgery (= 3 segments) scheduled by laparotomy, for primary hepatic cancer or secondary metastases, 4. Affiliation to the ''National security'' regimen or beneficiary of this regimen. Exclusion Criteria: 1. Emergency surgery, 2. Cirrhosis: depending on availability of CT and / or MRI imaging results, clinical examination, Biology (PT, Bilirubin) or histological results (preoperative biopsies in healthy liver) 3. Portal hypertension: depending on availability of imaging data, history of esophageal varices 4. Contraindication to fitting a tool for monitoring dynamic hemodynamic indices (case of esophageal varices for esophageal Doppler for example), 5. Benign tumors, 6. Associated procedures programmed at the same operating time (excluding hepatic surgery): programmed associated digestive resection (colorectal or pancreatic), 7. Laparoscopy, 8. Liver transplantation, 9. Woman pregnant or likely to be (without effective contraception) or breastfeeding, 10. Person in an emergency situation, adult person subject to a legal protection measure (adult under guardianship, guardianship or legal protection), or unable to express consent, 11. Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Optimization of cardiac flow by base water-electrolyte supply
optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
Control arm
increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.

Locations

Country Name City State
France Institut Paoli Calmettes Marseille

Sponsors (1)

Lead Sponsor Collaborator
Institut Paoli-Calmettes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the cardiac output optimization strategy on the occurrence of postoperative complications Assessment of the impact of an individualized protocol for optimizing perioperative cardiac flow guided by monitoring of dynamic indices of preload dependence during the post-hepatic resection phase on the occurrence of postoperative complications in major hepatic surgery, for primary hepatic cancer or metastatic origin. We retain as the primary endpoint, the percentage of patients with at least one postoperative complication regardless of the grade in the Dindo-Clavien classification. From Day 1 to Day 30 post-surgery
Secondary Evaluation of grade III-IV postoperative complication in the Dindo-Clavien classification To determine whether the strategy for optimizing cardiac output guided by dynamic dependence preload indices is associated with a difference in the incidence of occurrence of at least one grade III-IV postoperative complication in the Dindo-Clavien classification From Day 1 to Day 30 post-surgery
Secondary Evaluation of length of stay in the hospital To determine whether the cardiac output optimization strategy guided by the dynamic dependence preload indices is associated with a difference in the length of stay in the Continuing Care Unit, intensive care unit or length of hospital stay or on re-hospitalization rates From Day 1 to Day 30 post-surgery
Secondary Evaluation of mortality To determine whether the cardiac output optimization strategy guided by the dynamic dependence preload indices is associated with a difference in mortality at D30 and D90 On Day 1, Day 30 and Day 90 post-surgery
Secondary Evaluation occurrence of organ failures To determine whether the cardiac output optimization strategy guided by dynamic dependence preload indices has an impact on the occurrence of organ failures, which will be evaluated by the SOFA score per device from Day 1 to Day 7 postoperatively From Day 1 to Day 7 post-surgery
Secondary Evaluation of hemodynamic parameters To determine whether the cardiac output optimization strategy guided by dynamic dependence preload indices is associated with a difference on hemodynamic parameters From Day 0 to Day 1 post-surgery